In its update, GSK reported a 17% rise in specialty medicines across its HIV, cancer, and respiratory business to £2.93 ...

Gepotidacin inhibits DNA replication via two ... could claim 10 million deaths a year by 2050. "The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in ...

Blujepa (gepotidacin) is the first drug approved in a new class of antibiotics known as triazaacenaphthylene, which works differently from other antibiotics and has a lower potential for antibiotic ...

A promising new antibiotic, gepotidacin, emerged as a potential weapon against drug-resistant gonorrhea, according to a recent study published in The Lancet. The clinical trial, involving 628 ...

Another emerging therapy showing promise in addressing patients with recurrent UTIs is gepotidacin, based on the EAGLE-2 and EAGLE-3trial findings. How is gepotidacin’s mechanism of action ...

Panelists discuss how newer urinary tract infection (UTI) therapies such as pivmecillinam, sulopenem etzadroxil/probenecid, and gepotidacin demonstrate significantly lower resistance rates (below ...

Gonorrhea is a sexually transmitted disease caused by Neisseria gonorrhoeae bacteria A new oral antibiotic, gepotidacin, may treat gonorrhea The drug showed similar success rates to current ...

In this context, the emergence of gepotidacin represents a significant breakthrough in the fight against this disease. Gepotidacin is an oral antibiotic that works by inhibiting bacterial DNA ...

“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP. When communicating her patients, Anna Myers, CNP, places great ...